The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol

The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol

Abstract Background Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic treatments for later-phase clinical trials. Renal cell carcinoma (RCC), th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stephan Ursprung, Helen Mossop, Ferdia A. Gallagher, Evis Sala, Richard Skells, Jamal A. N. Sipple, Thomas J. Mitchell, Anita Chhabra, Kate Fife, Athena Matakidou, Gemma Young, Amanda Walker, Martin G. Thomas, Mireia Crispin Ortuzar, Mark Sullivan, Andrew Protheroe, Grenville Oades, Balaji Venugopal, Anne Y. Warren, John Stone, Tim Eisen, James Wason, Sarah J. Welsh, Grant D. Stewart
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Clinical trial protocol [MeSH]
Clear cell renal cell carcinoma [MeSH]
Phase II clinical trial [MeSH]
Bayesian adaptive trial
Olaparib [MeSH]
Cediranib [MeSH]
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/c51c1579691f49dabf5c4459307d8325
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares